Biomedical Engineering Reference
In-Depth Information
87. Domingo E, Laiho P, Ollikainen M,
BRAF screening as a low-cost
effective strategy for simplifying HNPCC genetic testing.
et al.
J Med Genet
2004; 41: 664-668. doi:10.1136/jmg.2004.020651.
88. Benlloch S, Paya A, Alenda C,
Detection of BRAF V600E mutation
in colorectal cancer: comparison of automatic sequencing and real-
time chemistry methodology.
et al.
J Mol Diagn
2006; 8: 540-543.
89. Italiano A, Hostein I, Soubeyran I,
KRAS and BRAF mutational
status in primary colorectal tumors and related metastatic sites:
biological and clinical implications.
et al.
2010; 17: 1429-
1434. Published on 20100105. doi:10.1245/s10434-009-0864-z.
90. Baldus SE, Schaefer KL, Engers R,
Ann Surg Oncol
et al.
Prevalence and heterogeneity
of
KRAS,
BRAF,
and
PIK3CA
mutations
in
primary
colorectal
2010; 16: 790-799. Published on 20100126. doi:10.1158/1078-0432.
CCR-09-2446.
91. Santini D, Spoto C, Loupakis F,
adenocarcinomas and their corresponding metastases.
Clin Cancer Res
High concordance of BRAF
status between primary colorectal tumours and related metastatic
sites: implications for clinical practice.
et al.
Ann Oncol
2010; 21: 1565.
doi:10.1093/annonc/mdq318.
92. Van Cutsem E, Dicato M, Arber N,
Molecular markers and biological
targeted therapies in metastatic colorectal cancer: expert opinion and
recommendations derived from the 11th ESMO/World Congress on
Gastrointestinal Cancer, Barcelona, 2009.
et al.
Ann Oncol
2010; 21 Suppl 6:
vi1-10. doi:10.1093/annonc/mdq273.
93. Ogino S, Nosho K, Kirkner GJ,
CpG island methylator phenotype,
microsatellite instability, BRAF mutation and clinical outcome in colon
cancer.
et al.
2009; 58: 90-96. Published on 20081002. doi:10.1136/
gut.2008.155473.
94. Di Nicolantonio F, Martini M, Molinari F,
Gut
Wild-type BRAF is
required for response to panitumumab or cetuximab in metastatic
colorectal cancer.
et al.
2008; 26: 5705-5712. Published on
20081110. doi:10.1200/JCO.2008.18.0786.
95. Souglakos J, Philips J, Wang R,
J Clin Oncol
Prognostic and predictive value
of common mutations for treatment response and survival in patients
with metastatic colorectal cancer.
et al.
2009; 101: 465-472.
Published on 20090714. doi:10.1038/sj.bjc.6605164.
96. Loupakis F, Ruzzo A, Cremolini C,
Br J Cancer
KRAS codon 61, 146 and
BRAF mutations predict resistance to cetuximab plus irinotecan in
KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
et al.
Br J
